CD8A and ovarian cancer: DEX can effectively inhibit the activation of IGF2 signal pathway, improve the immune function of ovarian cancer rats, inhibit the invasion and migration of ovarian cancer cells, and significantly increase the percentage of CD4+, CD8+ and the ratio of CD4+/CD8+ (Tian et al., 2019).